Hypothyroidism in pregnancy

Weiping Teng, Zhongyan Shan, Komal Patil-Sisodia, David S Cooper

Research output: Contribution to journalArticle

Abstract

Hypothyroidism is the most common pregnancy-related thyroid disorder, affecting 3-5% of all pregnant women. Subclinical hypothyroidism is more common than is overt hypothyroidism, and is usually defined as a serum thyroid-stimulating hormone (TSH) concentration greater than the pregnancy-specific reference range for each laboratory value, or by serum TSH concentrations greater than 2·5 mIU/L in the first trimester and greater than 3 mIU/L in the second and third trimesters. Some authors have defined subclinical hypothyroidism as a serum TSH between 5 and 10 mIU/L, and overt hypothyroidism as a serum TSH greater than 10 mIU/L, but this is not the commonly accepted definition. Once overt hypothyroidism is diagnosed, treatment with levothyroxine should be started to achieve serum TSH concentrations within the reference ranges for pregnancy as soon as possible. For patients with subclinical hypothyroidism, recommendations for therapy differ between various professional groups as a result of inconsistent data from both observational studies and clinical trials regarding the benefits for the mother or the child. Similarly, because benefits of therapy are still uncertain, universal screening of all pregnant women for subclinical hypothyroidism or thyroid autoimmunity is not recommended by most professional groups. During gestation, an increase in levothyroxine dose is required in more than 50% of women with previously diagnosed hypothyroidism, and can be managed by increasing the levothyroxine dose by 30% when pregnancy is confirmed.

Original languageEnglish (US)
Pages (from-to)228-237
Number of pages10
JournalThe Lancet Diabetes and Endocrinology
Volume1
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Hypothyroidism
Pregnancy
Thyrotropin
Thyroxine
Serum
Pregnant Women
Thyroid Gland
Reference Values
Third Pregnancy Trimester
Second Pregnancy Trimester
First Pregnancy Trimester
Autoimmunity
Observational Studies
Therapeutics
Mothers
Clinical Trials

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology
  • Medicine(all)

Cite this

Hypothyroidism in pregnancy. / Teng, Weiping; Shan, Zhongyan; Patil-Sisodia, Komal; Cooper, David S.

In: The Lancet Diabetes and Endocrinology, Vol. 1, No. 3, 2013, p. 228-237.

Research output: Contribution to journalArticle

Teng, Weiping ; Shan, Zhongyan ; Patil-Sisodia, Komal ; Cooper, David S. / Hypothyroidism in pregnancy. In: The Lancet Diabetes and Endocrinology. 2013 ; Vol. 1, No. 3. pp. 228-237.
@article{ae67f120a0f2412ba119ca6654aff9dc,
title = "Hypothyroidism in pregnancy",
abstract = "Hypothyroidism is the most common pregnancy-related thyroid disorder, affecting 3-5{\%} of all pregnant women. Subclinical hypothyroidism is more common than is overt hypothyroidism, and is usually defined as a serum thyroid-stimulating hormone (TSH) concentration greater than the pregnancy-specific reference range for each laboratory value, or by serum TSH concentrations greater than 2·5 mIU/L in the first trimester and greater than 3 mIU/L in the second and third trimesters. Some authors have defined subclinical hypothyroidism as a serum TSH between 5 and 10 mIU/L, and overt hypothyroidism as a serum TSH greater than 10 mIU/L, but this is not the commonly accepted definition. Once overt hypothyroidism is diagnosed, treatment with levothyroxine should be started to achieve serum TSH concentrations within the reference ranges for pregnancy as soon as possible. For patients with subclinical hypothyroidism, recommendations for therapy differ between various professional groups as a result of inconsistent data from both observational studies and clinical trials regarding the benefits for the mother or the child. Similarly, because benefits of therapy are still uncertain, universal screening of all pregnant women for subclinical hypothyroidism or thyroid autoimmunity is not recommended by most professional groups. During gestation, an increase in levothyroxine dose is required in more than 50{\%} of women with previously diagnosed hypothyroidism, and can be managed by increasing the levothyroxine dose by 30{\%} when pregnancy is confirmed.",
author = "Weiping Teng and Zhongyan Shan and Komal Patil-Sisodia and Cooper, {David S}",
year = "2013",
doi = "10.1016/S2213-8587(13)70109-8",
language = "English (US)",
volume = "1",
pages = "228--237",
journal = "The Lancet Diabetes and Endocrinology",
issn = "2213-8587",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Hypothyroidism in pregnancy

AU - Teng, Weiping

AU - Shan, Zhongyan

AU - Patil-Sisodia, Komal

AU - Cooper, David S

PY - 2013

Y1 - 2013

N2 - Hypothyroidism is the most common pregnancy-related thyroid disorder, affecting 3-5% of all pregnant women. Subclinical hypothyroidism is more common than is overt hypothyroidism, and is usually defined as a serum thyroid-stimulating hormone (TSH) concentration greater than the pregnancy-specific reference range for each laboratory value, or by serum TSH concentrations greater than 2·5 mIU/L in the first trimester and greater than 3 mIU/L in the second and third trimesters. Some authors have defined subclinical hypothyroidism as a serum TSH between 5 and 10 mIU/L, and overt hypothyroidism as a serum TSH greater than 10 mIU/L, but this is not the commonly accepted definition. Once overt hypothyroidism is diagnosed, treatment with levothyroxine should be started to achieve serum TSH concentrations within the reference ranges for pregnancy as soon as possible. For patients with subclinical hypothyroidism, recommendations for therapy differ between various professional groups as a result of inconsistent data from both observational studies and clinical trials regarding the benefits for the mother or the child. Similarly, because benefits of therapy are still uncertain, universal screening of all pregnant women for subclinical hypothyroidism or thyroid autoimmunity is not recommended by most professional groups. During gestation, an increase in levothyroxine dose is required in more than 50% of women with previously diagnosed hypothyroidism, and can be managed by increasing the levothyroxine dose by 30% when pregnancy is confirmed.

AB - Hypothyroidism is the most common pregnancy-related thyroid disorder, affecting 3-5% of all pregnant women. Subclinical hypothyroidism is more common than is overt hypothyroidism, and is usually defined as a serum thyroid-stimulating hormone (TSH) concentration greater than the pregnancy-specific reference range for each laboratory value, or by serum TSH concentrations greater than 2·5 mIU/L in the first trimester and greater than 3 mIU/L in the second and third trimesters. Some authors have defined subclinical hypothyroidism as a serum TSH between 5 and 10 mIU/L, and overt hypothyroidism as a serum TSH greater than 10 mIU/L, but this is not the commonly accepted definition. Once overt hypothyroidism is diagnosed, treatment with levothyroxine should be started to achieve serum TSH concentrations within the reference ranges for pregnancy as soon as possible. For patients with subclinical hypothyroidism, recommendations for therapy differ between various professional groups as a result of inconsistent data from both observational studies and clinical trials regarding the benefits for the mother or the child. Similarly, because benefits of therapy are still uncertain, universal screening of all pregnant women for subclinical hypothyroidism or thyroid autoimmunity is not recommended by most professional groups. During gestation, an increase in levothyroxine dose is required in more than 50% of women with previously diagnosed hypothyroidism, and can be managed by increasing the levothyroxine dose by 30% when pregnancy is confirmed.

UR - http://www.scopus.com/inward/record.url?scp=84886936679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886936679&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(13)70109-8

DO - 10.1016/S2213-8587(13)70109-8

M3 - Article

C2 - 24622371

AN - SCOPUS:84886936679

VL - 1

SP - 228

EP - 237

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

IS - 3

ER -